Elahe Salehi speaks to ecancer at the APAO 2019 meeting in Boston about the treatment pathways used at The Dana-Farber Cancer Institute for patients with triple-negative breast cancer.

She references the results of the IMpassion130 clinical trial and the use of atezolizumab in combination with nab-paclitaxel is the standard of care used at the Dana-Farber Cancer Institute for their metastatic patients.

Salehi discusses the adverse events associated with immunotherapy which can result in a delay in therapy.